implying that a shareholder with significant specific weight conditions and forces the company's initiatives is certainly not a good sign for the rest of the investors and those who would like to invest. anticipating a buyback news leaving open the suspicion of having been informed in advance is not serious for those who peddle it and for the company itself. all this has no relevance, when everyone thinks with their own head. as I mentioned in my previous post, today it seems clear to me that the announcement of a buyback is more interesting for the company than for the shareholders, unlike what has been led to believe. the announcement that it will be effective no earlier than December 2nd, fuels certain doubts, on the opportunity of wanting to stem short selling, which in fact persist more than before. rather, and I repeat, the company needs to reabsorb the fully paid shares by February 2025, to then put them back on the market and deliver them to their rightful owners. this is what the 50 million in the buyback dowry will be for, but not necessarily to counter or induce those who operate short to cover. the evidence of the numbers generated by the post-announcement market demonstrates that the company also has interests, that the price per share is as favorable as possible to the buyback by virtue of a concrete saving. the one who loses out, as usual, is that retail that in good faith, trusts what is passed off as certified.
- Forums
- ASX - By Stock
- NEU
- Ann: Notification of buy-back - NEU
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.69%
!
$14.20

Ann: Notification of buy-back - NEU, page-44
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B |
Open | High | Low | Value | Volume |
$13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $14.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.23 | 3278 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1300 | 14.030 |
1 | 500 | 14.000 |
1 | 357 | 13.970 |
1 | 30 | 13.900 |
1 | 700 | 13.700 |
Price($) | Vol. | No. |
---|---|---|
14.260 | 2920 | 1 |
14.300 | 1000 | 1 |
14.380 | 72 | 1 |
14.400 | 1000 | 1 |
14.460 | 434 | 1 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online